American Society of Hirudotherapy

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report

Case report published in Portuguese Journal of Cardiac Thoracic and Vascular Surgery (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportDrug DevelopmentAlves B et al. · Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 2025

Abstract

Unfractionated heparin is the main anticoagulant employed in the context of cardiovascular surgery. When a patient with heparin induced thrombocytopenia (HIT) is proposed for cardiac surgery, the anticoagulation management is challenging. Bivalirudin is an alternative to heparin in the perioperative setting. We present a rare case of a patient with HIT and cardiogenic shock that required bivalirudin use in the perioperative period of an urgent reoperation of recurrent mitral valve dysfunction. Although infrequent, the use of bivalirudin can be safe in high risk patients if adequate measures follow institutional protocols, as reported in this case.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansAnticoagulantsAntithrombinsHeart Valve Prosthesis ImplantationHeparinHirudinsMitral Valve InsufficiencyPeptide FragmentsRecombinant ProteinsReoperationShock, CardiogenicThrombocytopenia

Summary

Case report of a patient with heparin-induced thrombocytopenia and cardiogenic shock who received bivalirudin for perioperative anticoagulation during urgent reoperation for recurrent mitral valve dysfunction; authors report it can be safe when institutional protocols are followed.

Why This Matters for Hirudotherapy

This case report describes a patient with heparin-induced thrombocytopenia (HIT) and cardiogenic shock who received bivalirudin during the perioperative period of an urgent reoperation for recurrent mitral valve dysfunction, with a reportedly safe outcome under institutional protocols. The abstract discusses bivalirudin as an alternative to heparin in the perioperative setting but provides no detail on its mechanism beyond clinical use. This is a single case report involving no leeches or leech therapy. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Alves B, Veiga J, Morais I, Lima F, Paulo N. Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report. Port J Card Thorac Vasc Surg. 2025;32(1):55-58. doi:10.48729/pjctvs.448. PMID: 40327428

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.